The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...
Hosted on MSN15d
Myriad Genetics secures patents for cancer MRD testsThese patents build on three foundational MRD technology patents awarded to Myriad Genetics in 2024, which relate to cell-free DNA preparation methods and enable highly sensitive tumor-informed ...
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...
In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...
In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor ...
Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback